UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

(Amendment No.     )

Filed by the Registrant x

Filed by a Party other than the Registrant ¨

Check the appropriate box:

¨        Preliminary Proxy Statement	¨	Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
¨        Definitive Proxy Statement
x       Definitive Additional Materials
¨        Soliciting Material Pursuant to §240.14a-12

BioMarin Pharmaceutical Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x  No fee required.

¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1)  Title of each class of securities to which transaction applies:

(2)  Aggregate number of securities to which transaction applies:

(3)  Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)  Proposed maximum aggregate value of transaction:

(5)  Total fee paid:

¨ Fee paid previously with preliminary materials:

¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)  Amount Previously Paid:

(2)  Form, Schedule or Registration Statement No.:

(3)  Filing Party:

(4)  Date Filed:

BioMarin Pharmaceutical Inc.

May 23, 2005

Dear Shareholder:

I’m pleased to have this opportunity to introduce myself to you as the new Chief Executive Officer of BioMarin Pharmaceutical Inc. and to provide you with my perspective on our company. I believe in the significance of the BioMarin opportunity and I am committed to the goals of firmly establishing BioMarin as a leader in the biotechnology industry and increasing the value of your investment in BioMarin’s stock. I believe that your goals and mine are very much the same.

With the resignation of my predecessor in August of 2004, your Board was faced with a number of difficult decisions. Nonetheless, their judicious yet aggressive response has yielded substantial value to you, even in the absence of a permanent CEO. I believe the Board’s accomplishments in this short time are truly remarkable and include:

• Our recently-announced partnership with Serono, with an upfront payment of $25 million and milestone payments of up to $232 million;

• Our initiation of Phase 3 Clinical Trials of Phenoptin^™ for PKU;

• Our positive results from the Phase 3 extension study of Naglazyme in MPS VI;

• Our successful avoidance of a dilutive financing during a period when our stock price was unnaturally depressed;

• The successful retention of the BioMarin management and research teams during this period of significant uncertainty; and, if I may humbly add,

• The selection of myself to join BioMarin as the new CEO after what I’m advised was a thorough and highly selective search.

As a result of these diligent efforts, the price of your stock increased from $4.83 on August 12, 2004, the date on which my predecessor left, to $7.13 on May 19, 2005—an increase of 48%!

Despite these extraordinary achievements during what otherwise would be a troubled time for any company, a small group of dissident shareholders has launched a costly and divisive proxy fight in its attempt to gain three seats on your Board of Directors.

I caution you that you may be hearing shortly from this dissident group—headed by Caduceus Capital, an off-shore investment fund, and its affiliates—in their attempt to persuade you to vote your shares for their nominees. Although the Caduceus group and its affiliates own only 8% of BioMarin’s stock, they are seeking 43% of the seats on your Board of Directors.

In my brief time with BioMarin, I have been extremely impressed with the management team and Board of Directors. I am absolutely convinced that having a split Board—which is what would result if the Caduceus nominees were elected—would be divisive and disruptive, and could be very harmful to the momentum that has been generated at BioMarin.

In the coming weeks, I will be communicating with you regularly regarding our achievements and our goals. I also want you to know that you have my personal pledge that I am committed to increasing shareholder value.

I urge you to vote for your Board’s highly qualified nominees by signing, dating and returning the enclosed WHITE proxy card, and I thank you for your attention and anticipated support.

Sincerely,

Jean-Jacques Bienaimé

Chief Executive Officer and Director

IMPORTANT

YOUR VOTE IS IMPORTANT, REGARDLESS OF THE NUMBER OF SHARES YOU HAVE. TO ASSURE YOUR REPRESENTATION AT THE ANNUAL MEETING, PLEASE SIGN AND DATE THE ENCLOSED WHITE PROXY CARD AND RETURN IT TODAY IN THE PRE-ADDRESSED, POSTAGE-PAID ENVELOPE. I URGE YOU NOT TO SIGN, EVEN AS A PROTEST, ANY BLUE PROXY CARD THAT MAY BE SENT TO YOU.

If you have any questions, please call our proxy solicitor:

Morrow & Co., Inc. at 1-800-607-0088.